Aier Eye Hospital Group Co., Ltd.
爱尔眼科
300015
Shenzhen Stock Exchange
Company Profile
1. “Hierarchical Chain” Development Model Suitable for China’s National Conditions The hierarchical chain model of “Central City Hospital - Provincial Capital Hospital - Prefecture-Level Hospital - County-Level Hospital” has been established, as well as intra-city network formed by multiple hospitals in one city, clinics and Aier E-Stations. "Horizontal and vertical networks" are formed in different provinces, which not only achieves a rapid chain effect, but also meets the needs of people at all levels for ophthalmic medical services. 2. Leading Advantage of “Medical Treatment - Teaching – Scientific Research” Integration The industry status and influence of our company are increasingly enhanced with the establishment of Aier School of Ophthalmology, Central South University, Aier Eye Institute, Academician Workstation, etc. 3. Competitive Incentive Mechanism for Talents The Executive Stock Options, Restricted Stock Plans and Partnership Programs have been put into force in our company, encouraging the development of talents. 4. Leading Technology Advantage Our company keeps track of and introduces the up-to-date international ophthalmic diagnosis and treatment technology and advanced equipment, among which a large number of technologies have filled in the gaps in China. We provide multi-level medical services to patients.
Full description
The company is a national chain professional ophthalmic medical institution specialized in eye diseases’ diagnosis and treatment, surgical services and medical optometry. As the world’s largest ophthalmic chain group, Aier has formed unique leading brand advantages in medical network, professional services, industry talents, academic research, management mechanism and so on. There is a huge demand for ophthalmic medical services in China. From the perspective of the prevalence of ophthalmology, the substantial increase of the intensity of over-straining eyes for studying, working and entertainment in modern society results in a rising prevalence of various ophthalmologic diseases, especially the high incidence and younger age of myopia crowds. At the same time, cataracts and diabetic retinopathy and other age-related eye diseases caused by population aging continue to grow, which poses larger and higher requirements on the supply of medical cares. With the day-by-day rise of people’s income levels and the constant improvement of medical insurance system in China, the potential demand for ophthalmic medical treatment will be continuously translated into the real and effective demand and a large number of basic needs will be gradually upgraded to high-end demands. Under the joint action of demand growth and consumption upgrading, the market capacity of ophthalmic diagnosis and treatment will continue to expand.